Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.48 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | NSD2 | O96028 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | CASP1 | P29466 | 1/20 | 0.48 |
| ▸ | HTT | P42858 | 1/20 | 0.48 |
| ▸ | CASP7 | P55210 | 1/20 | 0.48 |
| ▸ | CASP6 | P55212 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.46 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.45 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17120711 | 0.87 | HTR3A (0.58) | KDM4ELMNAMAPTNSD2TSHR | |
| SCHEMBL17120705 | 0.87 | KDM4E (0.67) | KDM4ELMNAMAPTNSD2TSHR | |
| SCHEMBL17120712 | 0.86 | ESR2 (0.53) | KDM4ELMNAMAPTHTTESR2 | |
| SCHEMBL29662934 | 0.82 | KDM4E (0.44) | KDM4ELMNAMAPTNSD2TSHR | |
| SCHEMBL17099818 | 0.82 | KDM4E (0.44) | KDM4ELMNAMAPTNSD2TSHR | |
| SCHEMBL19052372 | 0.77 | TRPA1 (0.58) | NR3C1TRPA1ABL1ESR2CYP1A2 | |
| SCHEMBL17099871 | 0.77 | KDM4E (0.47) | KDM4ELMNAMAPTNSD2TSHR | |
| SCHEMBL17954830 | 0.76 | NR3C1 (0.49) | KDM4ELMNAMAPTSMN1; SMN2NR3C1 | |
| SCHEMBL4810527 | 0.74 | HTR3A (0.67) | KDM4ELMNAMAPTTSHRHTT | |
| SCHEMBL30480097 | 0.74 | HTR3A (0.67) | KDM4ELMNAMAPTTSHRHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2024-06-27 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2023-08-08 | — | — | US | disclosed |
| EP-3119761-B1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS INC (US) | 2023-06-07 | — | — | EP | disclosed |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | Amydis, Inc. | 2021-12-02 | — | — | US | disclosed |
| WO-2021055639-A1 | METHODS OF DETECTING NEUROLOGICAL DISORDERS VIA BINDING TO PHOSPHORYLATED TAU PROTEIN | SARRAF STELLA (US) | 2021-03-25 | — | — | WO | disclosed |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-03-02 | — | — | US | disclosed |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-04-23 | — | — | US | disclosed |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2019-08-06 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-06-26 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20170248616-A1 | IN VITRO COMPOSITIONS COMPRISING HUMAN SAMPLE AND AMYLOID TARGETING AGENT | Amydis, Inc. | 2017-08-31 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | Amydis, Inc. | 2016-11-10 | — | — | US | disclosed |
| WO-2015143185-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | AMYDIS DIAGNOSTICS (US) | 2015-09-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11718596-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | KDM4E 4807/4885LMNA 1263/4885MAPT 25/4885 |
| US-20200123118-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | KDM4E 4807/4885LMNA 1263/4885MAPT 25/4885 |
| US-20210369873-A1 | COMPOSITIONS AND METHODS FOR DETECTION OF TRAUMATIC BRAIN INJURY | S100B, FABP7, CRYAB | KDM4E 4796/4885LMNA 270/4885MAPT 38/4885 |
| US-20210371390-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | KDM4E 4807/4885LMNA 1263/4885MAPT 25/4885 |
| US-20240208916-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, CRYAA, APBA1 | KDM4E 4807/4885LMNA 1263/4885MAPT 25/4885 |
| US-20160326126-A1 | AMYLOID TARGETING AGENTS AND METHODS OF USING THE SAME | APP, APBA1, CRYAA | KDM4E 4804/4885LMNA 1283/4885MAPT 26/4885 |
| US-10370345-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | KDM4E 4807/4885LMNA 1263/4885MAPT 25/4885 |
| US-10934264-B2 | Amyloid targeting agents and methods of using the same | APP, CRYAA, APBA1 | KDM4E 4807/4885LMNA 1263/4885MAPT 25/4885 |
| US-10005745-B2 | Amyloid targeting agents and methods of using the same | APP, APBA1, CRYAA | KDM4E 4804/4885LMNA 1283/4885MAPT 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.